Replimune Group, Inc.
Company Stats
- Market Cap
- $1.2B
- as of Sep 30, 2026
- Shares Outstanding
- 94.2M
- Free Float
- 83.2%
Income Statement
- Operating Income
- -$319.9M
- Net Income
- -$313.9M
- EBITDA
- -$316.6M
- Non-cash Impairment
- $188,000
Cash Flow
- Free Cash Flow
- -$284.6M
- FCF Yield
- -22.8%
- Owner FCF Yield
- -25.4%
Balance Sheet
- Cash & Equivalents
- $209.0M
Returns & Capital
- SBC, 3Y Avg
- $33.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2026 | — | -$284.6M | — |
| FY2025 | — | -$198.9M | — |
| FY2024 | — | -$191.1M | — |
| FY2023 | — | -$130.3M | — |
| FY2022 | — | -$84.5M | — |
Annual filing data through FY ended March 31, 2026; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 28, 2026
Product Launch Watch
TUDRIQEV Prescriptions Start; Nautilus Opens Voyager Access
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
July 2, 2026
Small-Cap Signal
AI Infrastructure Capital Floods In While Biotech Trials Split
June 30, 2026
Filings Beige Book
Input Costs Squeeze Margins Even as Demand Holds Firm
TUDRIQEV Prescriptions Start; Nautilus Opens Voyager Access
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
July 2, 2026
Small-Cap Signal
AI Infrastructure Capital Floods In While Biotech Trials Split
June 30, 2026
Filings Beige Book
Input Costs Squeeze Margins Even as Demand Holds Firm